Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05131035 · ClinicalTrials.gov registry record · NA

Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk

A NA study of Psychosis and Prodromal Schizophrenia, sponsored by Northwell Health.

Recruiting
Registry status
NA
Development phase
54
Enrollment target
1
Study location

NCT05131035: Recruiting NA study of Psychosis and Prodromal Schizophrenia, sponsored by Northwell Health.

NCT05131035 is a NA study of Psychosis and Prodromal Schizophrenia that is actively recruiting participants, run by Northwell Health. The registered enrollment target is 54 participants, below the 177-participant average among 35 other Psychosis trials with a reported enrollment target (69% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05131035, a NA study of Psychosis and Prodromal Schizophrenia, is actively recruiting participants, sponsored by Northwell Health.

RECRUITING
Registry status
NA
Development phase
54 participants
Enrollment target
1
Study location

Study Summary

This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targeted cognitive training exercises and group support was developed to directly impact processing speed, and at the same time, boost motivation and engagement in adolescents at risk for schizophrenia and other psychotic disorders.

Primary Outcome

Change in processing speed domain score and individual measures within the domain.

Interventions

  • BEHAVIORAL SCORES (Specific COgnitive Remediation with Support)

Study Locations (1)

New York

  • Northwell Health- The Zucker Hillside Hospital - Glen Oaks

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2021-10-28
Est. Completion 2026-05-31
Phase NA
Northwell Health

370 total trials

What NCT05131035 shows while recruiting

NCT05131035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 177-participant average among 35 other Psychosis trials with a reported enrollment target (69% lower).

The record links to 3 conditions, with Psychosis appearing as the primary indexed condition, and to 1 intervention - of which SCORES (Specific COgnitive Remediation with Support) is the first listed.

NCT05131035 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT05131035 about?

NCT05131035 is a clinical study titled "Targeting Processing Speed Deficits to Improve Social Functioning and Lower Psychosis Risk". This 10 week intervention, Specific Cognitive Remediation with Surround (or SCORES), is designed to target processing speed, a cognitive domain related directly to social functioning, which in turn, represents a vulnerability factor for psychosis. This remotely-delivered intervention combining targe...

What is the current status of trial NCT05131035?

This trial is currently recruiting. It is a NA study. The enrollment target is 54 participants. The study started on 2021-10-28. Estimated completion is 2026-05-31.

What conditions does trial NCT05131035 study?

This clinical trial studies the following conditions: Psychosis, Prodromal Schizophrenia, Prodromal Symptoms.

What interventions are being tested in trial NCT05131035?

The interventions under investigation include: SCORES (Specific COgnitive Remediation with Support) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05131035?

This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05131035 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psychosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05131035's enrollment target sits among peer trials

54 23rd of 35 higher than 13 of 35 other Psychosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Psychosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01269853 · 54 participants · Phase 1

    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

  • NCT02390752 · 54 participants · Phase 1

    Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

  • NCT02991248 · 54 participants · NA

    Improve Dynamic Lateral Balance of Humans With SCI

  • NCT02993900 · 54 participants · NA

    Image-Guided Gynecologic Brachytherapy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05131035, the US trial registry maintained by the National Library of Medicine. NCT05131035 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.